Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which ...
In today’s ACT Brief, we spotlight the industry’s push to reduce site technology burden, AstraZeneca’s broad survival gains ...
Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...
Gain insight into how the MATTERHORN trial’s results across PD-L1 subgroups could expand access to immunotherapy and reshape ...
Addressing the imbalance in clinical trial workloads by empowering mid-level investigators and using AI to expand access to ...
Learn how increasing system complexity and patient-facing technologies are creating new burdens for clinical trial sites—and ...
ACT: The MATTERHORN trial showed a 22% reduction in the risk of death with the Imfinzi regimen. How significant is this ...
Examining how artificial intelligence can help identify true key opinion leaders in emerging markets to improve site ...
Highlighting how technology and mindset shifts can help expand breast cancer research leadership beyond high-income countries ...
Examining how shifting leadership patterns in breast cancer research signal growing international participation—and the ...
At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients ...
Revisit top insights from SCOPE Summit 2025, where industry leaders explored how artificial intelligence is reshaping trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback